Illumina introduces TruPath Genome, setting a new standard in genomic insight: San Diego Thursday, February 26, 2026, 16:00 Hrs [IST] Illumina, Inc. announced the launch of TruPat ...
TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases 40% increase in output ...
15d
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing
In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome solution and expanded clinical sequencing services, including supporting Florida State University’s new pediatric rare ...
A new whole genome platform integrates on-flow cell library prep and advanced informatics to deliver comprehensive variant ...
G-protein-coupled receptors (GPCRs) remain major drug targets, despite an incomplete understanding of how they signal through 16 non-visual G-protein signal transducers (collectively named the ...
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for ...
Illumina's launch of TruPath™ Genome sets a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and ...
TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results